State of Wyoming Invests $526,000 in Xenon Pharmaceuticals Inc. $XENE

State of Wyoming purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, Holdings Channel reports. The institutional investor purchased 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $526,000.

Several other hedge funds also recently modified their holdings of the company. Danske Bank A S bought a new stake in Xenon Pharmaceuticals during the 3rd quarter worth $32,000. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter worth about $33,000. Osaic Holdings Inc. raised its position in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $43,000. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 900 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Up 0.0%

XENE stock opened at $62.36 on Tuesday. The firm has a market cap of $6.03 billion, a PE ratio of -13.16 and a beta of 0.62. The stock has a 50-day moving average price of $61.57 and a 200-day moving average price of $55.22. Xenon Pharmaceuticals Inc. has a 1-year low of $35.60 and a 1-year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the prior year, the business posted ($1.07) EPS. On average, analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wells Fargo & Company restated an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Needham & Company LLC reduced their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director directly owned 1,870 shares in the company, valued at approximately $119,792.20. This represents a 84.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.